Alphaton Capital Corp (ATON)

$5.75 -0.20 (-3.36%)
Market Cap 6.03M
Revenue (ttm) 0.00
Net Income (ttm) -6.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 33,000
Avg Vol 80,736
Day's Range N/A - N/A
Shares Out 1.05M
Stochastic %K 38%
Beta 0.21
Analysts Hold
Price Target N/A

Company Profile

AlphaTON Capital Corp., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A...

Industry: Asset Management
Sector: Financial Services
Phone: 302 219 5556
Address:
Clarence Thomas Building, P.O. Box 4649 Road Town, Tortola, British Virgin Islands
GenghisGrene
GenghisGrene Oct. 2 at 9:11 PM
$ATON watch for the crypto treasury news! $OCEA $CWD
0 · Reply
_Julia
_Julia Oct. 2 at 7:16 PM
$ATON TON is a great token
0 · Reply
Trade_Stocks_Smoke_Rocks
Trade_Stocks_Smoke_Rocks Oct. 2 at 5:09 PM
$ATON got my pants around my ankles ready for this stock. When it goes I’ll turn my computer into a Jackson Pollock.
0 · Reply
Fixer00
Fixer00 Oct. 1 at 7:01 PM
$ATON hold onto your shares. something huge is coming this month to TON Overview: Wallet in Telegram (100M+ users) announced plans to launch tokenized U.S. stocks/ETFs via Kraken’s xStocks platform in October 2025. This positions TON as a gateway to traditional finance for Telegram’s 1B-user ecosystem.
0 · Reply
Mey636363
Mey636363 Oct. 1 at 6:27 PM
$ATON come on AH
0 · Reply
fatpie68
fatpie68 Oct. 1 at 3:37 PM
I don't think $HIT is buying crypto. They are using the $ATON blockchain technology to build their HITChain on The Open Network (TON) - and that's a very good thing. https://www.stocktitan.net/news/HIT/health-in-tech-and-alpha-ton-capital-sign-strategic-letter-of-intent-y3eycoxrvw45.html
1 · Reply
Trade_Stocks_Smoke_Rocks
Trade_Stocks_Smoke_Rocks Oct. 1 at 12:20 PM
$ATON CTB is over 400%, let’s get a good sized jump here.
0 · Reply
nick30017
nick30017 Oct. 1 at 6:23 AM
$ATON MUST SEE news dropped last night after market closed https://news.nuntiobot.com/article/2082e3e3-b448-40c7-9e8f-0939f793d269
0 · Reply
MashiSamurai
MashiSamurai Sep. 30 at 9:53 PM
$ATON Got news recently hoping for a bounce into 8-9$+
0 · Reply
yft212
yft212 Sep. 30 at 9:20 PM
$ATON This may be starting to show signs of life. Any guesses on price targets now that it's not Portage Bio?
1 · Reply
Latest News on ATON
Animoca Brands and AlphaTON Capital announce equity and token investments; AlphaTON intends to acquire GAMEE

Sep 30, 2025, 9:35 PM EDT - 4 days ago

Animoca Brands and AlphaTON Capital announce equity and token investments; AlphaTON intends to acquire GAMEE

Health In Tech and AlphaTON Capital Sign Strategic Letter of Intent to Develop HITChain

Sep 30, 2025, 8:00 AM EDT - 4 days ago

Health In Tech and AlphaTON Capital Sign Strategic Letter of Intent to Develop HITChain

HIT

AlphaTON Capital Corp Successfully Closes $71 million Financing and Completes Initial TON Token Acquisition

Sep 25, 2025, 2:45 PM EDT - 9 days ago

AlphaTON Capital Corp Successfully Closes $71 million Financing and Completes Initial TON Token Acquisition

AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem

Sep 3, 2025, 12:37 PM EDT - 4 weeks ago

AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Jul 25, 2025, 4:15 PM EDT - 2 months ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

Jun 25, 2025, 7:00 AM EDT - 3 months ago

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

Portage Biotech and Compedica Stock-for-Stock Exchange

Jun 9, 2025, 6:00 AM EDT - 4 months ago

Portage Biotech and Compedica Stock-for-Stock Exchange

Portage Biotech Stock Surges As It Prepares For Human Trial

Apr 28, 2025, 10:37 AM EDT - 5 months ago

Portage Biotech Stock Surges As It Prepares For Human Trial

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Apr 28, 2025, 6:00 AM EDT - 5 months ago

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Why Is Portage Biotech Stock Skyrocketing Friday?

Mar 28, 2025, 1:13 PM EDT - 6 months ago

Why Is Portage Biotech Stock Skyrocketing Friday?

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Mar 27, 2025, 6:02 PM EDT - 6 months ago

Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Mar 12, 2025, 8:00 AM EDT - 7 months ago

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Feb 12, 2025, 4:15 PM EST - 8 months ago

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Announces Completion of $2.15 Million Private Financing

Jan 30, 2025, 4:30 PM EST - 8 months ago

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Jan 6, 2025, 5:00 AM EST - 9 months ago

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Dec 12, 2024, 4:15 PM EST - 10 months ago

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Nov 26, 2024, 4:05 PM EST - 11 months ago

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Apr 12, 2024, 8:01 AM EDT - 1 year ago

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Mar 26, 2024, 8:01 AM EDT - 1 year ago

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Feb 28, 2024, 5:10 PM EST - 1 year ago

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Portage Biotech Reports Business and Strategic Update

Jan 4, 2024, 8:00 AM EST - 1 year ago

Portage Biotech Reports Business and Strategic Update

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Nov 28, 2023, 4:01 PM EST - 2 years ago

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Nov 6, 2023, 8:01 AM EST - 2 years ago

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Portage Biotech Announces $6.0 Million Registered Direct Offering

Sep 29, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Announces $6.0 Million Registered Direct Offering

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Sep 20, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023, 5:00 PM EDT - 2 years ago

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Portage Biotech to Present at Oppenheimer's 33rd Annual Healthcare Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Portage Biotech to Present at Oppenheimer's 33rd Annual Healthcare Conference

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

Mar 1, 2023, 8:00 AM EST - 2 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Feb 27, 2023, 4:05 PM EST - 2 years ago

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Feb 15, 2023, 8:00 AM EST - 2 years ago

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Nov 29, 2022, 4:43 PM EST - 3 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 10, 2022, 9:00 AM EST - 3 years ago

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

Nov 8, 2022, 8:00 AM EST - 3 years ago

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

Portage Biotech Provides Research and Development Update

Sep 14, 2022, 8:39 AM EDT - 3 years ago

Portage Biotech Provides Research and Development Update

Portage Biotech to Present at Upcoming Investor Conferences

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech to Present at Upcoming Investor Conferences

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

Aug 29, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

Portage Biotech Announces Leadership Updates

Aug 18, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Announces Leadership Updates

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Aug 1, 2022, 9:10 AM EDT - 3 years ago

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Jul 20, 2022, 4:07 PM EDT - 3 years ago

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Jul 20, 2022, 9:00 AM EDT - 3 years ago

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Jul 6, 2022, 4:05 PM EDT - 3 years ago

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Jun 6, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Apr 25, 2022, 8:00 AM EDT - 3 years ago

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

GenghisGrene
GenghisGrene Oct. 2 at 9:11 PM
$ATON watch for the crypto treasury news! $OCEA $CWD
0 · Reply
_Julia
_Julia Oct. 2 at 7:16 PM
$ATON TON is a great token
0 · Reply
Trade_Stocks_Smoke_Rocks
Trade_Stocks_Smoke_Rocks Oct. 2 at 5:09 PM
$ATON got my pants around my ankles ready for this stock. When it goes I’ll turn my computer into a Jackson Pollock.
0 · Reply
Fixer00
Fixer00 Oct. 1 at 7:01 PM
$ATON hold onto your shares. something huge is coming this month to TON Overview: Wallet in Telegram (100M+ users) announced plans to launch tokenized U.S. stocks/ETFs via Kraken’s xStocks platform in October 2025. This positions TON as a gateway to traditional finance for Telegram’s 1B-user ecosystem.
0 · Reply
Mey636363
Mey636363 Oct. 1 at 6:27 PM
$ATON come on AH
0 · Reply
fatpie68
fatpie68 Oct. 1 at 3:37 PM
I don't think $HIT is buying crypto. They are using the $ATON blockchain technology to build their HITChain on The Open Network (TON) - and that's a very good thing. https://www.stocktitan.net/news/HIT/health-in-tech-and-alpha-ton-capital-sign-strategic-letter-of-intent-y3eycoxrvw45.html
1 · Reply
Trade_Stocks_Smoke_Rocks
Trade_Stocks_Smoke_Rocks Oct. 1 at 12:20 PM
$ATON CTB is over 400%, let’s get a good sized jump here.
0 · Reply
nick30017
nick30017 Oct. 1 at 6:23 AM
$ATON MUST SEE news dropped last night after market closed https://news.nuntiobot.com/article/2082e3e3-b448-40c7-9e8f-0939f793d269
0 · Reply
MashiSamurai
MashiSamurai Sep. 30 at 9:53 PM
$ATON Got news recently hoping for a bounce into 8-9$+
0 · Reply
yft212
yft212 Sep. 30 at 9:20 PM
$ATON This may be starting to show signs of life. Any guesses on price targets now that it's not Portage Bio?
1 · Reply
Rasto2020
Rasto2020 Sep. 30 at 9:18 PM
$ATON it looks interesting
0 · Reply
IggyKoopa
IggyKoopa Sep. 30 at 9:15 PM
$ATON come on insiders.. Pump this with the group.
0 · Reply
DaBullRunner
DaBullRunner Sep. 30 at 9:13 PM
$ATON there it goes ICU is going to make a big run soon 🚨🚨🚨🚨🚨 Here’s why👇
0 · Reply
IggyKoopa
IggyKoopa Sep. 30 at 4:15 PM
$ATON back under $3 eventually. All pure telegram coins p&d.
0 · Reply
mymy2009
mymy2009 Sep. 30 at 1:28 PM
$ATON 🟢 $WOLF $BENF $EPOW $HIT $ATON Strategic LOI signed to co-develop HITChain, a blockchain-powered healthcare claims platform
0 · Reply
mymy2009
mymy2009 Sep. 30 at 12:55 PM
$ATON 🟢 https://www.webullapp.com/news-detail/13600545905857536?theme=1&hl=en&color=2&_v=1&tickerId=925308073&disSymbol=ATON&sourcePage=Stock_NewsList&sp=0&hl=en
0 · Reply
GenghisGrene
GenghisGrene Sep. 26 at 12:30 PM
$ATON there she blows! Crypto treasury. $CWD
0 · Reply
yft212
yft212 Sep. 26 at 12:08 PM
$ATON https://cryptorank.io/news/feed/34969-nasdaq-listed-alphaton-capital-invests-30m-in-ton-tokens
0 · Reply
QRNAKQARNUI
QRNAKQARNUI Sep. 25 at 9:28 PM
$ATON what is going on here
0 · Reply
_Julia
_Julia Sep. 25 at 8:00 PM
$ATON The exhibit is a press release (Ex. 99.1) on a 6‑K announcing the close and the initial TON buy. It does not include a resale registration or selling‑stockholder prospectus, that will be a separate filing. As long as the resale isn’t on file and not effective, the seller pool is smaller, which supports a stronger move.
1 · Reply
georgeroberts10
georgeroberts10 Sep. 25 at 7:39 PM
$ATON AlphaTON Capital Corp Successfully Closes $71 million Financing and Completes Initial TON Token Acquisition
0 · Reply
_Julia
_Julia Sep. 25 at 7:21 PM
$ATON This is the “we closed” filing we wanted. It sets the stage for a headline‑driven move during market hours. It’s not the resale registration and not a confirmed “TON purchased” update. Those are still to come, with the “purchases started” headline likely the next domino, followed by the resale registration filing.
1 · Reply